---
title: "阿爾凱默斯預計 2025 年專有產品銷售額將超過 10 億美元，隨着食慾素研發管線的推進"
description: "Alkermes plc 預計 2025 年專有產品銷售將創下超過 10 億美元的紀錄，這得益於第二季度的強勁表現和其 orexin 管線的進展。首席執行官 Richard F. Pops 強調了持續的盈利能力、無債務以及超過 10 億美元的現金。第二季度收入達到 3.907 億美元，專有產品淨銷售額為 3.072 億美元，同比增長 14%。公司有望達到或超過其財務指導，預計專有產品銷售將繼續增長"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/250649067.md"
published_at: "2025-07-29T19:01:27.000Z"
---

# 阿爾凱默斯預計 2025 年專有產品銷售額將超過 10 億美元，隨着食慾素研發管線的推進

> Alkermes plc 預計 2025 年專有產品銷售將創下超過 10 億美元的紀錄，這得益於第二季度的強勁表現和其 orexin 管線的進展。首席執行官 Richard F. Pops 強調了持續的盈利能力、無債務以及超過 10 億美元的現金。第二季度收入達到 3.907 億美元，專有產品淨銷售額為 3.072 億美元，同比增長 14%。公司有望達到或超過其財務指導，預計專有產品銷售將繼續增長。分析師對 alixorexton 的安全性和監管路徑表示謹慎樂觀，而管理層對其數據和產品的有效性保持信心

Earnings Call Insights: Alkermes plc (ALKS) Q2 2025 Management View Richard F. Pops, CEO, described the quarter as "very successful" and highlighted "strong commercial and financial performance" with Alkermes "on track to deliver on our key objectives across the business" for 2025. He stated, "With sustained profitability now, no debt and more than...

### Related Stocks

- [ALKS.US - 阿爾凱默斯](https://longbridge.com/zh-HK/quote/ALKS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Irish Court Approves Avadel Pharmaceuticals Acquisition by Alkermes | The Irish High Court has approved the acquisition of Avadel Pharmaceuticals plc by Alkermes plc. The court sanctioned th | [Link](https://longbridge.com/zh-HK/news/275510100.md) |
| Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares | Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, has reported the disposal of common shares of the | [Link](https://longbridge.com/zh-HK/news/271991860.md) |
| Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close | Alkermes (NASDAQ: ALKS) presented at the J.P. Morgan Healthcare Conference, highlighting its strong growth foundation as | [Link](https://longbridge.com/zh-HK/news/272469823.md) |
| Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares | Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported the disposal of common shares of the com | [Link](https://longbridge.com/zh-HK/news/271362738.md) |
| FDA Grants Breakthrough Therapy Designation to Alkermes' Alixorexton for Narcolepsy Type 1 | Alkermes plc has received Breakthrough Therapy designation from the FDA for its investigational drug alixorexton, aimed  | [Link](https://longbridge.com/zh-HK/news/271647276.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
